PROCEPT BioRobotics

General Information
Business:

We are a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. Our proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver our Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. 

(Note: PROCEPT BioRobotics upsized its IPO at pricing on Sept. 14, 2021, by increasing the number of shares to 6.56 million – up from 5.5 million – and pricing the stock at $25 – $1 above the top of $22-to-$24 range – to raise $164 million.)

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees: 205
Founded: 2021
Contact Information
Address 900 Island Drive, Redwood City, CA, 94065, US
Phone Number (650) 232-7200
Web Address http://www.procept-biorobotics.com
View Prospectus: PROCEPT BioRobotics
Financial Information
Market Cap $947.83mil
Revenues $21.0 mil (last 12 months)
Net Income $-54.7 mil (last 12 months)
IPO Profile
Symbol PRCT
Exchange NASDAQ
Shares (millions): 6.6
Price range $25.00 - $25.00
Est. $ Volume $164.0 mil
Manager / Joint Managers BofA Securities/ Goldman Sachs
CO-Managers Cowen/ Guggenheim Securities/ SVB Leerink
Expected To Trade: 9/15/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change